Abstract 5183: Development of an aerosol-based immunotherapy for lung cancer

Abstract

Lung cancer is one of the leading causes of cancer death and the second most cancer in the world. Compared to systematic administration, local delivery of therapeutic agents to the lung increases their accumulation in lung cancer cells and reduces the toxicity in other organs. We previously discovered an anti-PD-L1 peptide that can be potentially uses for lung cancer therapy. This project aims to develop an aerosolized formulation of the anti-PD-L1 peptide for the treatment of lung cancer. We hypothesize that the aerosolized peptide has higher accumulation in the lung compared to systematic formulations, leading to high therapeutic index with less side effects. We developed a spray freeze-drying procedure and optimized the formulation to prepare the peptide dry powders. The median mass aerodynamic diameter (MMAD) and geometric standard deviation (GSD) of the aerosols were determined by an 8-stage Andersen Cascade Impactor. The morphology of the aerosols was studied using a scanning electron microscope (SEM). The stability of the aerosols in lung fluid was evaluated. Blocking assay suggested that the aerosolized formulation maintains the blocking efficiency of the peptide. Intratracheal administration of the peptide dry powder shows a high accumulation of the peptide in the lung. Citation Format: Yongren Li, Zhen Zhao, John Fetse, Reaid Hasan, Umar-Farouk Mamani, Yuhan Guo, Kun Cheng. Development of an aerosol-based immunotherapy for lung cancer. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5183.